BM (hons), MRCPCH, MD

Training and education

Bachelor of Medicine with Honours and Distinction in Final Medicine, University of Southampton, 2003
Membership of the Royal College of Paediatrics and Child Health (MRCPCH), 2006
Entered onto Specialist Register (CCT Paediatrics), 2015
Doctor of medicine (MD), University of Southampton, 2017
Fellow of the Royal College of Paediatrics and Child Health (FRCPCH), 2017
Member of the British Empire (MBE) for services to paediatrics and the COVID-19 response, 2021

Dr Cathie qualified as a doctor in 2003 and trained in paediatrics in the Wessex region from 2004. She's worked here at University Hospital Southampton since she completed her training in 2015.

Experience

Dr Cathie joined the Trust as a locum consultant in 2015 before taking on a substantive consultant post in 2016.

In her work as part of the general paediatric team, Dr Cathie is involved in the assessment, investigation and management of acute and chronic conditions affecting children and young people.

Dr Cathie has an active role in paediatric research. She is the associate director for paediatrics of the NIHR clinical research facility at UHS. She's the principal investigator for a number of research studies involving children and young people at UHS and the co-chair of GAPRUKI, a national network for general paediatric research in the UK and Ireland.

Dr Cathie is a APLS (advanced paediatric life support) instructor. She's actively involved in the paediatric innovation, education and research (PIER) network and part of the organising team for their annual conference.

Key achievements

Successfully completing an MD while doing clinical paediatric training.
Awarded an MBE in 2021 for her services to paediatrics and the COVID-19 response.
Organising the successful PIER conference (with the rest of the team) for 10 years, educating child health staff across Wessex together.
Key Publications:
- Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
  RECOVERY Collaborative, The Lancet. Child & Adolescent Health, 22 Jan 2024, 8(3):190-200
- Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants
  Cathie K et al, HARMONIE Study Group, N Engl J Med, 389(26):2425-2435, Dec 2023
- Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A Randomised Controlled Trial
  Kelly E, Cathie K et al, J of Infection, online June 2023, https://doi.org/10.1016/j.jinf.2023.06.007
- Immunogenicity and Reactogenicity of BNT162b2 and mRNA1273 COVID-19 Vaccines Given as Fourth Dose Boosters in the COV-BOOST Randomised Trial Following Two Doses of ChAdOx1 nCov-19 or BNT162b2 and a Third Dose of BNT162b2
  Munro APS, Cathie K et al, Lancet Infectious Diseases Aug 2022, Volume 22, Issue 8, 1131-1141
- Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial
  X Liu, K Cathie et al, Journal of Infection, June 2022;84(6):795-813
- Priorities for child health research across the UK and Ireland
  Cathie K, et al, Archives of Disease in Childhood 2022; 107:474-478
- Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
  Munro, APS, Cathie, K et al, The Lancet 2021, Volume 398, Issue 10318, 2258 – 2276
- Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
  Voysey M, et al, The Lancet 2021, Volume 397, Issue 10277, 881 – 891
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
  Voysey M, et al, The Lancet January 2021, Volume 397, (10269), 99 – 111
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
  Ramasamy MN, et al, The Lancet 2020, Volume 396, Issue 10267, 1979 – 1993
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
  Folegatti PM, et al, The Lancet August 2020, Volume 396, Issue 10249, 467 – 478
- Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study
  Saul N. Faust, Katrina Cathie et al, BMC Pediatrics 2019;19:50
- Low dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas Aeruginosa infection in cystic fibrosis
  K Cathie, R Howlin, S Faust, J Webb et al; Molecular Therapy, Vol. 25, No 10, Oct 2017

Awards and prizes

MBE for services to paediatrics and the COVID-19 response, 2021
Wessex PAFTAs – winner of consultant unsung hero award, 2019
Wessex PAFTAs – nominated as consultant unsung hero/supervisor of the year, 2017, 2018, 2022, 2023, 2024
Wessex PAFTAs – nominated as senior trainee of the year, 2015
American Thoracic Society Abstract Scholarship (for quality of abstract), 2014
Best oral presentation, Southampton Faculty of Medicine Conference 2013
Best trainee presentation at Wessex Paediatric Winter Meeting 2013
Best audit/presentation at UHS Clinical Effectiveness Conference, 2008
Royal College of Paediatrics and Child Health Medical Student Prize, 2003
Prize for best paediatric research project, 2002

Research

Dr Cathie is the associate director of the NIHR clinical research facility at UHS for paediatrics. She is co-chair of GAPRUKI (general and adolescent paediatric research in the UK and Ireland) network. She has led multiple commercial and non-commercial NIHR portfolio studies, including a number of vaccine studies. She was one of the national leads for a large multicentre study (HARMONIE) of an RSV preventative treatment for babies, results published in The Lancet.

She is co-lead for an NIHR HTA grant looking at IV treatments for acute severe asthma in children (2025) and co-applicant on 3 other NIHR HTA grants, bronchiolitis in babies, reflux treatment in babies and steroids in neonatal meningitis.

Dr Cathie's research focuses on common conditions that affect children and young people in the general paediatric setting and vaccines to prevent illness.

Contact

You can contact Dr Cathie via her secretary, Caroline Wain on 023 8120 4310 or send an email.